Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™

  • participants needed
  • sponsor
    Michael J. Fox Foundation for Parkinson's Research
Updated on 28 January 2023
positron emission tomography


Directly examine whether early (6-month) imaging with DaTscan and [¹⁸F] AV-133 will provide an early signal of disease progression in recently diagnosed untreated PD patients.


A multi-center study to assess progression of DaTscan and [¹⁸F] AV-133 imaging in PD patients. Participants will be followed for at least 18 months. Approximately 50 PD participants will be recruited from up to 5 sites. All participants will be comprehensively assessed at baseline and every six months thereafter. Participants will undergo imaging assessments with DaTscan and [¹⁸F] AV-133, clinical (motor, neuropsychiatric and cognitive) assessments, as well as biospecimen collection for biomic analysis. Data will be collected by each site under uniformly established protocols and data will be stored and analyzed at designated core facilities.

Condition Parkinson Disease
Clinical Study IdentifierNCT04507139
SponsorMichael J. Fox Foundation for Parkinson's Research
Last Modified on28 January 2023

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note